Therapy and management of systemic AL (primary) amyloidosis | Zendy

Giovanni Palladini | Zendy; Vittorio Perfetti | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Therapy and management of systemic AL (primary) amyloidosis

Author(s) -

Giovanni Palladini,

Vittorio Perfetti

Publication year - 2006

Publication title -

schweizerische medizinische wochenschrift

Language(s) - English

Resource type - Journals

ISSN - 0036-7672

DOI - 10.4414/smw.2006.11479

Subject(s) - medicine , amyloidosis , immunoglobulin light chain , al amyloidosis , intensive care medicine , troponin , amyloid (mycology) , natriuretic peptide , supportive psychotherapy , organ dysfunction , cardiac dysfunction , antibody , pathology , immunology , heart failure , sepsis , myocardial infarction

The optimal treatment of immunoglobulin light chain amyloidosis (AL) patients requires early diagnosis, correct amyloid typing, effective treatment and careful supportive therapy. In the last few years the therapeutic arsenal for the management of AL has been considerably enriched. Cardiac dysfunction can be accurately monitored by measuring the serum concentration of natriuretic peptide type-B and cardiac troponins and the quantitative test for circulating free light chains allows an easy assessment of haematological response to chemotherapy. These new tools can be combined in order to maximise the improvement of organ dysfunction and minimise toxicity, adapting the intervention to each patient.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research